Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.
By H. Bartelink, P. Maingon, P. Poortmans, C. Weltens, A. Fourquet, J. Jager, D. Schinagl, B. Oei, C. Rodenhuis, J. Horiot and 12 more. The Lancet Oncology, 2015
606 citations recorded by the source corpus.
Subfields: Cancer Research, Pathology and Forensic Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/67d4c7e86ee0b8dc62990e0c09a05d20e9ae5f2e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
Citations in the corpus
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (2018, background): “In another instance of de-escalation, the Panel believed that ‘boost’ could be omitted in patients aged 60, with low grade tumor features and/or favorable tumor biology who will be taking adjuvant endocrine therapy [18, 19].”
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, background): “It is indicated for patients who have unfavourable risk factors for local control such as: age <50 years, grade 3 tumours, extensive DCIS, vascular invasion or non-radical tumour excision (focally— otherwise further surgery should be advocated) [I, A] [70, 71].”